Overview

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

Status:
Active, not recruiting

Trial end date:
2023-03-31

Target enrollment:

Participant gender:

Summary

In this trial, treatment efficacy and safety of retreatment with 1st generation epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI)s(Gefitinib/Erlotinib), will be assessed in patients with sensitizing EGFR mutation positive Non-Squamous Cell Carcinoma patients who previously treated with EGFR TKI and cytotoxic chemotherapy

Phase:

Phase 2

Details

Lead Sponsor:

Korea University Guro Hospital

Collaborator:

Chong Kun Dang Pharmaceutical Corp.